Tyra Biosciences

Yahoo Finance • last month

Biotech Stock Up 372% Gets Sold as New Pick Rises 40% in 2026

On February 17, 2026, Boone Capital Management sold out its entire Cogent Biosciences(NASDAQ:COGT) stake, liquidating 945,042 shares previously worth $13.57 million. What happened According to an SEC filing dated February 17, 2026, Boone... Full story

Yahoo Finance • last month

This Biotech Stock Has Surged 250% in a Year as One Investor Discloses $10 Million New Position

On February 17, 2026, Boone Capital Management disclosed a new position in Tyra Biosciences(NASDAQ:TYRA), acquiring 398,482 shares worth $10.48 million at quarter’s end. What happened According to a Securities and Exchange Commission (SE... Full story

Yahoo Finance • last month

Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million Exit

Key Points 5AM Venture Management sold 365,053 shares of Dianthus Therapeutics in the fourth quarter. The quarter-end position value decreased by $14.36 million as a result of the sale, which marked a full exit from Dianthus. The position... Full story

Yahoo Finance • 3 months ago

Tyra Biosciences price target raised to $53 from $37 at Wedbush

Wedbush analyst Robert Driscoll raised the firm’s price target on Tyra Biosciences (TYRA) to $53 from $37 and keeps an Outperform rating on the shares. The firm notes BridgeBio (BBIO) announced positive topline Phase 3 data for infigratini... Full story

Yahoo Finance • 10 months ago

H.C. Wainwright reiterates Buy rating on Tyra Biosciences stock at $30

Investing.com - H.C. Wainwright has reiterated its Buy rating and $30.00 price target on Tyra Biosciences (NASDAQ:TYRA), representing over 200% upside from the current price of $9.57, following the company’s announcement that the first p... Full story

Yahoo Finance • 10 months ago

Tyra Biosciences Doses First Patient in Phase 2 Study of TYRA-300 in Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302)

-TYRA-300 is the only orally administered investigational agent in clinical development for IR NMIBC- -Initial 3-month complete response (CR) data expected to be reported in 1H 2026- CARLSBAD, Calif., June 30, 2025 /PRNewswire/ -- Tyra B... Full story

Yahoo Finance • 10 months ago

Tyra Biosciences begins dosing in Phase 2 trial for TYRA-300 in bladder cancer

Tyra Biosciences , Inc. (NASDAQ:TYRA), a clinical-stage biotech company with a market capitalization of $484 million, announced Monday that it has dosed the first patient in its SURF302 Phase 2 clinical study of TYRA-300 for the treatment... Full story

Yahoo Finance • 2 years ago

16 Most Promising Long-Term Stocks According to Analysts

In this piece, we will take a look at the 16 most promising long-term stocks according to analysts. If you want to skip our overview of long term investing, then you can take a look at 5 Most Promising Long-Term Stocks According to Analyst... Full story